NIRV — Nirvana Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$5.06m
- CA$5.16m
Annual cashflow statement for Nirvana Life Sciences, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 6 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.314 | -0.254 | -5.66 | -1.49 | -0.873 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.046 | -0.01 | 4.81 | 0.691 | 0.308 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.248 | 0.109 | 0.265 | 0.376 | 0.357 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.021 | -0.156 | -0.49 | -0.333 | -0.19 |
| Capital Expenditures | — | — | 0 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -0.101 | 0 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | — | -0.101 | 0 | — |
| Financing Cash Flow Items | — | -0.015 | — | 0.11 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.022 | 0.629 | 0.002 | 0.31 | 0.179 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.002 | 0.474 | -0.589 | -0.023 | -0.011 |